TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06403501: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Efficacy and Safety of Clascoterone Cream 1% in Treatment of Subjects With Facial Acne Vulgaris

Sponsor: Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 692 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,723,520

Rescue Site Savings

+$7,730,196

Unlock Full NCT06403501 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06403501 Rescue Dossier →